Welcome to the ATGesundheit Institute
The mission of the ATGesundheit Institute is to carry out observational studies on patients undergoing investigational Oncolytic Virus & Cancer Immunotherapy treatment in cooperation with medical professionals. ATGesundheit Institute also reviews patient medical histories to enhance their health and safety. Oncolytic virus therapy combined with other therapies is a promising approach with potential to extend survival time and to improve quality of life.
Oncolytic immunotherapy is a new approach to cancer treatment. For ATGesundheit Institute by Rapo Yerape BH Ltd., Dr. Gesundheit and his team review patient’s medical data and evaluate if they are eligible for Oncolytic Virus treatment.
Please read our recently published research: Effective Treatment of Glioblastoma Multiforme With Oncolytic Virotherapy: A Case-Series in the May 2020 issue of Frontier in Oncology.
Dr. Beni Gesundheit, MD PhD
Scientific Advisor, Rapo Yerape BH Ltd.
OV Research
The ability to genetically engineer oncolytic viruses (OV) in order to minimize side effects and improve the selective targeting of tumor cells is opening up novel opportunities for treating cancer. Understanding the mechanisms involved and the complex interaction between the viruses and the immune system will undoubtedly help guide the development of new strategies.
EDITED BY: Benjamin Gesundheit and Joshua P. Rosenzweig
PUBLISHED IN: Frontiers in Oncology and Frontiers in Immunology
FAQ
Oncolytic Virus (OV) Immunotherapy utilizes selected viruses to target tumor cell types without harming healthy tissue. Their selectivity is attributed to different biological features of the surface of cancer tumor cells that are absent in normal human cells. Once the infected tumor cell is destroyed by OVs, the amplified OVs can infect and target adjacent tumor cells, eventually eliminating the entire tumor mass.
OV Therapy provides a direct tumor-killing (oncolytic) effect and a parallel activation of the patient’s immune system against tumor cells (immunotherapy). Since 2010 immunotherapy has been revolutionizing oncology treatment and has provided new biotechnology products for standard clinical practice. These products have included the first licensed OV Therapy indicated for the treatment of melanoma, which stands as proof of concept for the entire OV Therapy field.
Dr. Thaller’s patients have experienced relatively minimal side effects. Fever is a side effect that is also a sign of a successful immune response. When necessary fever can be prevented or reduced using standard analgesics. No long-term side effects have been reported.
The cost depends mostly on the individual treatment interval. Estimated costs for the first year which involves intensive treatment is between 50-100 thousand Euro. Please note that OV therapy is investigational and may not be covered by health insurance.
The above estimate does not include diagnostic testing or travel expenses.
Diagnostics are usually covered for patients with German health insurance. It may also be covered by other insurance policies. One would need to check regarding their individual policy.
Depending on where one lives travel expenses will differ. Please assess your travel costs in order to come to the clinic in Germany for treatment.
Questions?
Please take the opportunity to contact us either with a general query or to begin the patient application process.